solute carrier family 16 member 5Genealiases: MCT5 · MCT6
Q-omics provides the consensus-scored SLC16A5 profile across patient tissues and cancer cell-line models. SLC16A5 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, SLC16A5 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, SLC16A5 RNA expression shows 18,458 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LGG, KIRC, and THYM as cancer lineages where SLC16A5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC16A5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC16A5 survival associations across molecular data types. SLC16A5 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC16A5 RNA expression–survival associations across cancer types. High SLC16A5 expression shows unfavorable associations in LGG, PAAD, COAD and SKCM, but favorable associations in HNSC and UCS. The LGG Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for SLC16A5 RNA expression.
This table summarizes SLC16A5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for SLC16A5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC16A5 shows lower tumor expression in KIRC, THCA, LUAD, KIRP, KICH and LUSC. The KIRC box plot shows higher SLC16A5 RNA expression in normal versus tumor tissue (log2 FC = −3.416, t-test p < 0.001).
This table shows molecular features associated with SLC16A5 in patient tissues and cancer cell lines. In patient samples, SLC16A5 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC16A5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
